Clinical experience: FOLFIRI/XELIRI after failure of a fluoropyrimidine/platinum combination regimen in advanced gastroesophageal adenocarcinoma.

Inês Leão,Joana Marinho,Ema Silva Neto,Helena Guedes,Ana Joaquim,Antonio Pinto,Enrique Dias,Telma Costa,Sandra Custódio,Andreia Capela

Clinical experience: FOLFIRI/XELIRI after failure of a fluoropyrimidine/platinum combination regimen in advanced gastroesophageal adenocarcinoma.

2021

Inês Leão
Joana Marinho
Ema Silva Neto
Helena Guedes
Ana Joaquim
Antonio Pinto
Enrique Dias
Telma Costa
Sandra Custódio
Andreia Capela

e16104Background: Portugal has the highest gastric cancer incidence in western Europe. In our institution, FOLFIRI/XELIRI is the standard second line (2L) chemotherapy (CT) in advanced gastroesopha...

Keywords:

Internal medicine
Medicine
gastroesophageal adenocarcinoma
western europe
Regimen
Chemotherapy
second line
cancer incidence
Oncology
XELIRI
FOLFIRI

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations